Background
Phase III non-inferiority RCT (ACOSOG Z0011). 856 women with T1-T2 invasive breast cancer undergoing BCS with 1 or 2 sentinel lymph node (SLN) macrometastases. All patients received whole breast irradiation and adjuvant systemic therapy (chemotherapy and/or hormonal therapy). This is the 10-year outcomes report. Randomized to axillary lymph node dissection (ALND) vs SLNB alone.
Interventions and follow up
Arm A: Sentinel lymph node biopsy (SLNB) alone — no ALND
Arm B: Completion ALND (full axillary dissection)
Primary endpoint: Overall survival (non-inferiority)
mFollow up: Median 9.25 year
Arm B: Completion ALND (full axillary dissection)
Primary endpoint: Overall survival (non-inferiority)
mFollow up: Median 9.25 year
Results
10-year OS: 86.3% (SLNB) vs 83.6% (ALND); non-inferiority criterion met
10-year DFS: 80.2% (SLNB) vs 78.2% (ALND), P=.32 — not significant
10-year locoregional recurrence: 1.5% (SLNB) vs 0.5% (ALND) — not significantly different
10-year axillary recurrence: Low in both arms (<1%)
10-year DFS: 80.2% (SLNB) vs 78.2% (ALND), P=.32 — not significant
10-year locoregional recurrence: 1.5% (SLNB) vs 0.5% (ALND) — not significantly different
10-year axillary recurrence: Low in both arms (<1%)
Adverse events
Main adverse events: ALND was associated with significantly higher rates of lymphedema, paresthesias, and decreased shoulder range of motion. No excess morbidity with SLNB. Axillary morbidity was the primary driver of quality-of-life difference between arms.
Conclusions
At 10-year follow-up, SLNB alone remains non-inferior to completion ALND in patients with 1-2 positive SLNs undergoing BCS + WBI + adjuvant systemic therapy. ALND does not improve OS or DFS and causes substantially more arm morbidity. ALND can be safely omitted in this population.
Key Limitations
Key Limitations: Enrolled exclusively BCS patients receiving WBI — not applicable to mastectomy patients (see ALLIANCE Z11102 for that setting). As shown by Jagsi et al (JCO 2014), many patients received high tangents or formal nodal RT, meaning some axillary RT may have been unintentionally delivered. Excluded patients with matted nodes, three or more positive SLNs, or patients not receiving WBI. The non-inferiority design accepted a pre-specified margin — the observed OS difference of 2.7% at 10 years remains a consideration.
Clinical Context
Z0011 has fundamentally changed surgical practice — ALND is no longer the standard of care for 1-2 positive SLNs in BCS patients receiving WBI. NCCN, ASCO, and SSO guidelines now recommend SLNB alone in this setting. The trial redefined the role of regional nodal management in early breast cancer.
References